Health Canada Canada
Skip first menu (access key: X)
Fran├žais Contact Us Help Search Canada Site
Healthy Living Health Care Diseases & Conditions Health Protection Media Room
Health Canada Online
Accueil
Warnings / Advisories
arrow
Back to Warnings
Information
arrow What to look for: Ephedra/ephedrine
arrow Frequently Asked Questions
 

 

2002-01
January 9, 2002

Advisory

Health Canada requests recall of certain products containing Ephedra/ephedrine

OTTAWA- Health Canada is requesting a recall from the market of certain products containing Ephedra/ephedrine after a risk assessment concluded that these products pose a serious risk to health. Adverse events including stroke, heart attacks, heart rate irregularities, seizures, psychoses and deaths have been reported in association with the use of some products containing Ephedra/ephedrine. Ephedra refers to several related species of herbs. Ephedrine is one of many chemical derivatives of this herb.

This voluntary recall deals with products that are marketed without approval. These include:

  • Ephedra/ephedrine products having a dose unit of more than 8 mg of ephedrine or with a label recommending more than 8 mg/dose or 32 mg/day and/or are labelled or implied for use exceeding seven days;

  • all combination products containing Ephedra/ephedrine together with stimulants (e.g. caffeine) and other ingredients which might increase the effect of Ephedra/ephedrine in the body. A full table of ingredients containing caffeine is attached to this advisory;

  • Ephedra/ephedrine products with labelled or implied claims for appetite suppression, weight loss promotion, metabolic enhancement, increased exercise tolerance, body-building effects, euphoria, increased energy or wakefulness, or other stimulant effects.

Health Canada advises those Canadians who may be consuming these products to stop using them, and return them to their points of sale. Canadians suffering from heart conditions, high blood pressure and diabetes are among those particularly at risk.

Currently, the maximum allowable dosages for Ephedra/ephedrine in products is 8 mg ephedrine/single dose or 32mg ephedrine/day. Products containing Ephedra which are marketed for traditional medicine, will continue to be available, provided they do not contain caffeine and that the ephedrine content does not exceed 8 mg/dose to a maximum of 32 mg/day.

If a consumer has concerns about a product with a Drug Identification Number (DIN), and is not sure if the recommended dosage exceeds the 32 mg ephedrine/day dose limit, they should consult with their pharmacist. Consumers who identify remaining products on the shelves can call their regional Health Canada offices to report complaints. Their contact information is provided as an attachment.

Health Canada is issuing letters to Canadian manufacturers, distributors and importers requesting that they discontinue sale of these products and that the products be recalled from all levels of the market, including retail. A customs lookout has also been issued, to ensure that these products are not imported into Canada.

A health advisory was issued by Health Canada in June of last year, advising Canadians not to use products containing the herb Ephedra, in combination with caffeine and other stimulants, for purposes of weight loss, body building or increased energy. At the time of that advisory, 60 adverse events had been reported in Canada related to the use of Ephedra/ephedrine. Since then, a product which combined large doses of ephedrine with caffeine has been reported as a contributing factor in one death in Canada.

Health Canada will be issuing a regulatory letter to manufacturers of products which exceed this recommended dosage. Products with DINs that are being sold as nasal decongestants and have doses equal to or less than the upper limits of 8 mg ephedrine/dose and 32 mg ephedrine/day will continue to be available.

Health Canada will continue to monitor reports of adverse events associated with Ephedra/ephedrine, and will take further action if necessary. A random market survey will be undertaken within 6 months of the requested recall to determine whether these products have found their way back onto the Canadian market. Non-compliant products will be removed from the shelves.

- 30 -


Media Inquiries:
Ryan Baker
Media Relations
Health Canada
(613) 941-8189

Public Inquiries:
(613) 957-2991

To report complaints, the regional contacts are:

Health Products and Food Branch Inspectorate Operational Centres

Atlantic

Annette Daley
Suite 1625, 1505 Barrington St.
Halifax, Nova Scotia
B3J 3Y6
Tel: (902) 426-5350
Fax: (902) 426-6676

Manitoba and Saskatchewan

Robert Scales
510 Lagimodière Blvd.
Winnipeg, Manitoba
R2J 3Y1
Tel: (204) 983-5453
Fax: (204) 984-2155

Québec

Alain Bérubé
1001 ouest, rue St-Laurent
Longueil, Québec
J4K 1C7
Tel: (450) 646-1353, ext. 232
Fax: (450) 928-4455

Western

Dennis Shelley
3155 Willingdon Green
Burnaby, British Columbia
V5G 4P2
Tel: (604) 666-3704
Fax: (604) 666-3149

Ontario

Jean-Marc Charron
2301 Midland Avenue
Scarborough, Ontario
M1P 4R7
Tel: (416) 973-1466
Fax: (416) 973-1954

 

 

Last Updated: 2002-01-09

Top

Important Notices